MedPage Today (4/22, George) reports, “Neurofilament light (NfL) levels in blood corresponded with hallmarks of Alzheimer’s disease progression, an analysis of” 1,583 “older adults in North America” indicated. The study revealed that “longitudinal NfL levels were linked to baseline cerebrospinal fluid (CSF) biomarkers, MRI measures, PET imaging, and poor cognitive performance among Alzheimer’s Disease Neuroimaging Initiative Study (ADNI) participants.” The findings were published online in JAMA Neurology
Related Links:
— “Blood Test Tracks Alzheimer’s Progression, “Judy George, MedPage Today, April 22, 2019